TY - JOUR T1 - Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12-17 Years - Arizona, July-December 2021. AU - Lutrick,Karen, AU - Rivers,Patrick, AU - Yoo,Young M, AU - Grant,Lauren, AU - Hollister,James, AU - Jovel,Krystal, AU - Khan,Sana, AU - Lowe,Ashley, AU - Baccam,Zoe, AU - Hanson,Hanna, AU - Olsho,Lauren E W, AU - Fowlkes,Ashley, AU - Caban-Martinez,Alberto J, AU - Porter,Cynthia, AU - Yoon,Sarang, AU - Meece,Jennifer, AU - Gaglani,Manjusha, AU - Burns,Joy, AU - Mayo Lamberte,Julie, AU - Nakayima Miiro,Flavia, AU - Bissonnette,Adam, AU - LeClair,Lindsay, AU - Kutty,Preeta K, AU - Romine,James K, AU - Stefanski,Elisha, AU - Edwards,Laura J, AU - Ellingson,Katherine, AU - Gerald,Joe K, AU - Bedrick,Edward J, AU - Madhivanan,Purnima, AU - Krupp,Karl, AU - Gerald,Lynn B, AU - Thompson,Mark, AU - Burgess,Jefferey L, Y1 - 2021/12/31/ PY - 2021/12/30/entrez PY - 2021/12/31/pubmed PY - 2022/1/8/medline SP - 1761 EP - 1765 JF - MMWR. Morbidity and mortality weekly report JO - MMWR Morb Mortal Wkly Rep VL - 70 IS - 5152 N2 - The BNT162b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine has demonstrated high efficacy in preventing infection with SARS-CoV-2 (the virus that causes COVID-19) in randomized placebo-controlled Phase III trials in persons aged 12-17 years (referred to as adolescents in this report) (1); however, data on real-word vaccine effectiveness (VE) among adolescents are limited (1-3). As of December 2021, the Pfizer-BioNTech vaccine is approved by the Food and Drug Administration (FDA) for adolescents aged 16-17 years and under FDA emergency use authorization for those aged 12-15 years. In a prospective cohort in Arizona, 243 adolescents aged 12-17 years were tested for SARS-CoV-2 by reverse transcription-polymerase chain reaction (RT-PCR) each week, irrespective of symptoms, and upon onset of COVID-19-like illness during July 25-December 4, 2021; the SARS-CoV-2 B.1.617.2 (Delta) variant was the predominant strain during this study period. During the study, 190 adolescents contributed fully vaccinated person-time (≥14 days after receiving 2 doses of Pfizer-BioNTech vaccine), 30 contributed partially vaccinated person-time (receipt of 1 dose or receipt of 2 doses but with the second dose completed <14 days earlier), and 66 contributed unvaccinated person-time. Using the Cox proportional-hazards model, the estimated VE of full Pfizer-BioNTech vaccination for preventing SARS-CoV-2 infection was 92% (95% CI = 79%-97%), adjusted for sociodemographic characteristics, health information, frequency of social contact, mask use, location, and local virus circulation. These findings from a real-world setting indicate that 2 doses of Pfizer-BioNTech vaccine are highly effective in preventing SARS-CoV-2 infection among Arizona adolescents. CDC recommends COVID-19 vaccination for all eligible persons in the United States, including persons aged 12-17 years. SN - 1545-861X UR - https://www.unboundmedicine.com/medline/citation/34968373/Interim_Estimate_of_Vaccine_Effectiveness_of_BNT162b2__Pfizer_BioNTech__Vaccine_in_Preventing_SARS_CoV_2_Infection_Among_Adolescents_Aged_12_17_Years___Arizona_July_December_2021_ DB - PRIME DP - Unbound Medicine ER -